Ten-Year Outcomes of Sirolimus-Eluting Versus Zotarolimus-Eluting Coronary Stents in Patients With Versus Without Diabetes Mellitus (SORT OUT III)
Autor: | Manan Pareek, Jens F. Lassen, Leif Thuesen, Kevin Kris Warnakula Olesen, Evald Høj Christiansen, Morten Madsen, Steen Dalby Kristensen, Lisette Okkels Jensen, Hans Erik Bøtker, Michael Maeng |
---|---|
Rok vydání: | 2020 |
Předmět: |
CLINICAL-OUTCOMES
medicine.medical_specialty Denmark medicine.medical_treatment Coronary Artery Disease 030204 cardiovascular system & hematology Coronary Angiography Revascularization ANGIOGRAPHY Risk Assessment 03 medical and health sciences Postoperative Complications 0302 clinical medicine Cause of Death Internal medicine Diabetes mellitus Diabetes Mellitus medicine Humans In patient Zotarolimus 030212 general & internal medicine Myocardial infarction Retrospective Studies Sirolimus business.industry Incidence Drug-Eluting Stents Odds ratio EFFICACY medicine.disease Confidence interval Survival Rate REGISTRY SAFETY Cardiology REVASCULARIZATION IMPLANTATION Cardiology and Cardiovascular Medicine business Immunosuppressive Agents Follow-Up Studies Forecasting medicine.drug |
Zdroj: | Olesen, K K W, Pareek, M, Madsen, M, Jensen, L O, Christiansen, E H, Thuesen, L, Lassen, J F, Kristensen, S D, Bøtker, H E & Maeng, M 2020, ' Ten-Year Outcomes of Sirolimus-Eluting Versus Zotarolimus-Eluting Coronary Stents in Patients With Versus Without Diabetes Mellitus (SORT OUT III) ', American Journal of Cardiology, vol. 125, no. 3, pp. 349-353 . https://doi.org/10.1016/j.amjcard.2019.10.042 Olesen, K K W, Pareek, M, Madsen, M, Jensen, L O, Christiansen, E H, Thuesen, L, Lassen, J F, Kristensen, S D, Bøtker, H E & Maeng, M 2020, ' Ten-Year Outcomes of Sirolimus-Eluting Versus Zotarolimus-Eluting Coronary Stents in Patients With Versus Without Diabetes Mellitus (SORT OUT III) ', The American Journal of Cardiology, vol. 125, no. 3, pp. 349-353 . https://doi.org/10.1016/j.amjcard.2019.10.042 Olesen, K K W, Pareek, M, Madsen, M, Jensen, L O, Christiansen, E H, Thuesen, L, Lassen, J F, Kristensen, S D, Bøtker, H E & Maeng, M 2019, ' Ten-Year Outcomes of Sirolimus-Eluting Versus Zotarolimus-Eluting Coronary Stents in Patients With Versus Without Diabetes Mellitus (SORT OUT III) ', The American Journal of Cardiology . https://doi.org/10.1016/j.amjcard.2019.10.042 |
ISSN: | 0002-9149 |
Popis: | We compared 10-year clinical outcomes in diabetes and nondiabetes patients treated with Endeavor zotarolimus-eluting (ZES) or Cypher sirolimus-eluting coronary stents (SES). A total of 1,162 patients were randomized to ZES (169 with diabetes) and 1,170 patients were randomized to SES (168 with diabetes). Patients were further stratified by diabetes status at the time of inclusion. A subgroup of patients with diabetes (n = 88) underwent angiographic re-evaluation 10 months after stent implantation. End points included a combined end point of death or myocardial infarction, and the individual end points of death, myocardial infarction, and revascularization. In patients with diabetes, we found no difference in the combined end point (odds ratio [OR] 0.81, 95% confidence interval [CI] 0.53 to 1.24), death (OR 0.80, 95% CI 0.51 to 1.25), or in MI (OR 1.07, 95% CI 0.60 to 1.91). However, diabetics with ZES more frequently underwent coronary revascularization compared with SES patients (OR 1.93, 95% CI 1.05 to 3.66). In patients without diabetes, ZES and SES had similar 10-year rates of all end points (death: OR 1.13, 95% CI 0.93 to 1.39; MI: OR 0.80, 95% CI 0.61 to 1.05; revascularization: OR 0.81, 95% CI 0.61 to 1.09). Landmark analysis from 5 to 10 years showed no difference in outcomes between SES and ZES in either subgroup. In conclusion, at 10 years, SES and ZES performed similarly in patients with and without diabetes. Although coronary revascularization was more prevalent in diabetes patients with ZES, this may, in part, have been related to the angiographic follow-up that was offered to a subgroup of diabetes patients. |
Databáze: | OpenAIRE |
Externí odkaz: |